Clinical Trial

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Name: A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — clinical trial record (NCT03952559)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BREEZE-AD-PEDS

Completed Phase 3

View on ClinicalTrials.gov →

Summary

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Protocol Amendment History 1 change

critical Trial completed 2026-08-06

Trial Details

NCT Number	NCT03952559
Lead Sponsor	Eli Lilly and Company Collaborators: Incyte Corporation
Conditions	Atopic Dermatitis
Enrollment	516 participants
Start Date	2019-05-24
Primary Completion	2022-04-24 (estimated)
Study Completion	2026-05-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-05